NASDAQ:AARD Aardvark Therapeutics (AARD) Stock Price, News & Analysis $10.50 +0.49 (+4.90%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Aardvark Therapeutics Stock (NASDAQ:AARD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aardvark Therapeutics alerts:Sign Up Key Stats Today's Range$9.67▼$10.8150-Day Range$7.00▼$12.8652-Week Range$4.88▼$19.58Volume22,053 shsAverage Volume112,131 shsMarket Capitalization$227.81 millionP/E RatioN/ADividend YieldN/APrice Target$31.25Consensus RatingBuy Company OverviewAardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Read More… Receive AARD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aardvark Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AARD Stock News HeadlinesCantor Fitzgerald Analysts Raise Earnings Estimates for AARDMay 20 at 2:51 AM | americanbankingnews.comAardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal FunctionsMay 19, 2025 | globenewswire.comGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.May 23, 2025 | Premier Gold Co (Ad)Cantor Fitzgerald Remains a Buy on Septerna, Inc. (SEPN)May 18, 2025 | theglobeandmail.comRoyal Bank of Canada Cuts Aardvark Therapeutics (NASDAQ:AARD) Price Target to $20.00May 18, 2025 | americanbankingnews.comAardvark Therapeutics Reports Phase 3 HERO Trial Progress for ARD-101 in Prader-Willi Syndrome and Financial Results for Q1 2025May 16, 2025 | nasdaq.comAardvark Therapeutics, Inc.: Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 15, 2025 | finanznachrichten.deAardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 14, 2025 | globenewswire.comSee More Headlines AARD Stock Analysis - Frequently Asked Questions How have AARD shares performed this year? Aardvark Therapeutics' stock was trading at $13.30 on January 1st, 2025. Since then, AARD shares have decreased by 21.1% and is now trading at $10.50. View the best growth stocks for 2025 here. How were Aardvark Therapeutics' earnings last quarter? Aardvark Therapeutics, Inc. (NASDAQ:AARD) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by $0.01. When did Aardvark Therapeutics IPO? Aardvark Therapeutics (AARD) raised $100 million in an initial public offering on Friday, February 14th 2025. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets acted as the underwriters for the IPO. When did the company's quiet period expire? Aardvark Therapeutics' quiet period expired on Tuesday, March 25th. Aardvark Therapeutics had issued 5,888,000 shares in its public offering on February 13th. The total size of the offering was $94,208,000 based on an initial share price of $16.00. During the company's quiet period, insiders and any underwriters involved in the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. Who are Aardvark Therapeutics' major shareholders? Aardvark Therapeutics' top institutional investors include Decheng Capital LLC (18.06%), Cormorant Asset Management LP (3.69%), Braidwell LP (2.30%) and Adage Capital Partners GP L.L.C. (1.15%). Insiders that own company stock include Tien-Li Lee and Nelson Sun. View institutional ownership trends. How do I buy shares of Aardvark Therapeutics? Shares of AARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/14/2025Today5/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AARD Previous SymbolNASDAQ:AARD CIK1774857 WebN/A Phone(858) 225-7696FaxN/AEmployees18Year FoundedN/APrice Target and Rating Average Stock Price Target$31.25 High Stock Price Target$50.00 Low Stock Price Target$20.00 Potential Upside/Downside+190.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares21,696,000Free FloatN/AMarket Cap$233.23 million OptionableN/A BetaN/A A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:AARD) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.